Table 2.
HR (95% CI) | ||||
Group 1 <3.00 ng/L |
Group 2 3.0–6.21 ng/L |
Group 3 6.22–<14 ng/L |
Group 4 ≥14 ng/L |
|
No | 679 | 324 | 324 | 172 |
MACE | n=25 (3.7%) | n=30 (9.3%) | n=59 (18.2%) | n=40 (23.3%) |
Model 1 | 1 (Reference) | 1.65 (0.97 to 2.81) | 2.65 (1.64 to 4.27) | 4.20 (2.51 to 7.02) |
Model 2 | 1 (Reference) | 1.52 (0.89 to 2.59) | 2.41 (1.48 to 3.91) | 3.82 (2.27 to 6.43) |
Model 3 | 1 (Reference) | 1.52 (0.89 to 2.61) | 2.38 (1.47 to 3.88) | 3.79 (2.26 to 6.39) |
Model 4 | 1 (Reference) | 1.68 (0.97 to 2.92) | 2.31 (1.39 to 3.84) | 3.27 (1.88 to 5.70) |
Coronary event | n=14 (2.1%) | n=17 (5.3%) | n=41 (12.7%) | n=27 (15.7%) |
Model 1 | 1 (Reference) | 1.69 (0.83 to 3.44) | 3.39 (1.82 to 6.29) | 5.23 (2.7 to 10.14) |
Model 2 | 1 (Reference) | 1.61 (0.78 to 3.29) | 3.25 (1.74 to 6.07) | 5.5 (2.84 to 10.64) |
Model 3 | 1 (Reference) | 1.57 (0.76 to 3.22) | 3.09 (1.65 to 5.79) | 5.14 (2.65 to 9.98) |
Model 4 | 1 (Reference) | 1.42 (0.71 to 2.89) | 2.76 (1.44 to 5.31) | 4.50 (2.26 to 9.02) |
Stroke event | n=11 (1.6%) | n=13 (4.0%) | n=20 (6.2%) | n=17 (9.9%) |
Model 1 | 1 (Reference) | 1.59 (0.71 to 3.57) | 1.94 (0.91 to 4.14) | 3.84 (1.75 to 8.43) |
Model 2 | 1 (Reference) | 1.47 (0.65 to 3.29) | 1.77 (0.83 to 3.79) | 3.19 (1.42 to 7.16) |
Model 3 | 1 (Reference) | 1.47 (0.65 to 3.31) | 1.70 (0.79 to 3.66) | 3.16 (1.41 to 7.10) |
Model 4 | 1 (Reference) | 1.03 (0.50 to 2.09) | 1.13 (0.57 to 2.14) | 1.27 (0.69 to 2.62) |
All-cause mortality | n=8 (1.2%) | n=7 (2.2%) | n=16 (4.9%) | n=21 (12.2%) |
Model 1 | 1 (Reference) | 1.13 (0.41 to 3.14) | 1.99 (0.83 to 4.76) | 6.14 (2.61 to 14.46) |
Model 2 | 1 (Reference) | 1.13 (0.41 to 3.14) | 1.78 (0.73 to 4.35) | 4.87 (1.99 to 11.88) |
Model 3 | 1 (Reference) | 1.14 (0.41 to 3.16) | 1.79 (0.73 to 4.38) | 4.87 (1.99 to 11.88) |
Model 4 | 1 (Reference) | 1.01 (0.40 to 1.15) | 1.09 (0.43 to 2.76) | 2.07 (1.05 to 3.01) |
Models are defined as follows: model 1=adjusted for age and gender; model 2=adjusted for model 1 + presence of hypertension or diabetes mellitus, current smoking status, systolic blood pressure, postprandial blood glucose, total cholesterol, high-density lipoprotein cholesterol, antihypertensive medication use and antidiabetic medication use; model 3=adjusted for model 2 + estimated glomerular filtration rate; model 4=adjusted for model 3 + high-sensitivity C reactive protein and N-terminal pro-B-type natriuretic peptide (both after logarithmic transformation).
hs-cTnT, highly sensitive cardiac troponin T; MACE, major adverse cardiovascular event.